Targeting the Microenvironment in Acute Myeloid Leukemia
- 29 April 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Hematologic Malignancy Reports
- Vol. 10 (2), 126-131
- https://doi.org/10.1007/s11899-015-0255-4
Abstract
The bone marrow microenvironment plays a critical role in the development, progression, and relapse of acute myeloid leukemia (AML). Similar to normal hematopoietic stem cells, AML blasts express receptors on their surface, allowing them to interact with specific components of the marrow microenvironment. These interactions contribute to both chemotherapy resistance and disease relapse. Preclinical studies and early phase clinical trials have demonstrated the potential for targeting the tumor-microenvironment interactions in AML. Agents currently under investigation include hypoxia-inducible agents and inhibitors of CXCR4 and adhesion molecules such as VLA-4 and E-selectin.Keywords
This publication has 59 references indexed in Scilit:
- CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemiaJCI Insight, 2013
- A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemiaBlood, 2012
- High Expression of the Very Late Antigen-4 Integrin Independently Predicts Reduced Risk of Relapse and Improved Outcome in Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2010
- Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100Blood, 2009
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AMLBlood, 2009
- DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responsesProceedings of the National Academy of Sciences, 2009
- Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemiaBlood, 2009
- Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumabBlood, 2008
- Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemiaBlood, 2006
- mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth MachineryCell, 2002